Drug Reduces Daily "Off" Time For Parkinson Patients

Main Category: Parkinson's Disease
Also Included In: Neurology / Neuroscience;  Clinical Trials / Drug Trials
Article Date: 10 Apr 2007 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (3 votes)

Healthcare Prof:4 stars

4 (3 votes)


Parkinson disease patients taking the drug, ropinirole 24-hour prolonged release significantly reduced their daily "off" time in which Parkinson's symptoms like tremor, slowness, stiffness, and walking difficulty return as drugs wear off, according to a study published in the April 3, 2007, issue of Neurology®, the scientific journal of the American Academy of Neurology.

The study involved 393 people with Parkinson disease who weren't responding optimally to the widely used treatment for Parkinson, levodopa. For the study, half of the group took the prolonged release version of the drug ropinirole, called ropinirole 24-hour, and levodopa for six months. The other half took placebo and levodopa. Other Parkinson disease medications were not changed during the study.

Researchers found those people taking the drug reduced their average daily "off" time by 2.1 hours compared to .3 hours in the placebo group.

"Ropinirole 24-hour prolonged release, when taken with levodopa, is effective in reducing daily 'off' time for Parkinson patients who aren't getting the best results from levodopa," said study author Rajesh Pahwa, MD, with the University of Kansas Medical Center in Kansas City, Kansas, and Fellow of the American Academy of Neurology. "We also found the drug helped improve quality of life and motor function."

Among those taking ropinirole, researchers found significant improvements in troublesome Parkinson symptoms, quality of life, depression, emotional well-being, stigma, and sleep. Over half of the people in the ropinirole group were classified as much improved" or "very much improved" compared to 14 percent in the placebo group. Those taking ropinirole were also able to reduce their dosage of levodopa.

According to the study, common side effects were involuntary movements, nausea, dizziness, drowsiness, hallucinations, and sudden drops in blood pressure. The 24-hour prolonged release ropinirole appears to be as effective as immediate release ropinirole and better tolerated.

The study was supported by GlaxoSmithKline and Skye Pharma, makers of prolonged release ropinirole.

The American Academy of Neurology, an association of more than 20,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as epilepsy, dystonia, migraine, Huntington's disease, and dementia.

For more information about the American Academy of Neurology, visit http://www.aan.com.

American Academy of Neurology (AAN)
1080 Montreal Ave.
St. Paul, MN 55116
United States
American Academy of Neurology

Article adapted by Medical News Today from original press release.
Visit our parkinson's disease section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Mark Brown. "Drug Reduces Daily "Off" Time For Parkinson Patients." Medical News Today. MediLexicon, Intl., 10 Apr. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/67344.php>

APA
Mark Brown. (2007, April 10). "Drug Reduces Daily "Off" Time For Parkinson Patients." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/67344.php.

Please note: If no author information is provided, the source is cited instead.


Parkinson's Disease

What is Parkinson's Disease?

Parkinson's disease is a gradually progressive, degenerative neurologic disorder which typically impairs the patient's motor skills, speech, writing, as well as some other functions. Read more...

Most Popular Articles



Follow Our Parkinson's Disease News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Parkinson's Disease Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »